Novo Nordisk

EU#2 - From Humble Beginnings to Global Powerhouse

Tokyo

Invested

Community Contributor

Published

11 Apr 25

Updated

04 May 25

Tokyo's Fair Value

DKK 851.04

57.2% undervalued

04 May

DKK 363.90

-60.1%

11.7%

Author's Valuation

DKK 851.0

57.2% undervalued

Tokyo's Fair Value

Narrative

Updates1

Shared on01 May 25

Tokyo has increased revenue growth from 14.0% to 22.5%.

Tokyo'sFair Value

DKK 851.0

57.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

8.43%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.92%

Calculation

DKK 194.70b

Earnings '29

24.00x

PE Ratio '29

DKK 4.67t

Market Cap '29

DKK 4.67t

Market Cap '29

4.36b

No. shares '29

DKK 1.07k

Share Price '29

DKK 1.07k Share Price '29

Discounted to 2024 @ 4.74% p.a.

DKK 850.92

Fair Value '24